Monte Rosa Therapeutics(GLUE)
Focus: Monte Rosa Therapeutics is a publicly traded biotech company specializing in small molecule cancer drugs that modulate protein degradation pathways, operating as an early-stage oncology-focused innovator. The company trades on NASDAQ under ticker GLUE and is headquartered in Boston.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
19+26 this month
Hot — 31 jobs added in 30d
Net +26 (31 new, 5 removed). Aggressive expansion phase.
Should You Work at Monte Rosa Therapeutics?
AI assessmentBest suited for early-career or mission-driven professionals comfortable with pre-commercial biotech risk in exchange for equity upside and hands-on involvement in a differentiated oncology platform.
Why Work Here
- Recently IPO'd with $224M cash on hand (FY 2025), providing runway and growth capital for a differentiated technology platform in protein degradation—a validated oncology mechanism.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$76M
Pipeline & Clinical Trials
MRT-6160
Healthy VolunteersClinical Trials (1)
NCT06597799First-in-human Study of MRT-6160 in Healthy Subjects
Phase 1Help build intelligence for Monte Rosa Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.